## Table of Contents

### November 2015 • Volume 14 • Number 11

#### Highlights of This Issue 2409

**SMALL MOLECULE THERAPEUTICS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>2441</td>
<td>Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors</td>
<td>Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Duda, Kelly Jacques, Brendon Ladd, Celina M. D’Cruz, Zinda M. Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, and Emma L. Jenkins</td>
<td>Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors. Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Duda, Kelly Jacques, Brendon Ladd, Celina M. D’Cruz, Zinda M. Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, and Emma L. Jenkins.</td>
</tr>
<tr>
<td>2452</td>
<td>Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression</td>
<td>Beverly A. Teicher, Eric Polley, Mark Kunkel, David Evans, Thomas Silvers, Rene Delosh, Julie Lauteman, Chad Ogle, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Anne Monks, and Joel Morris</td>
<td>A novel inhibitor of AKT1–PDPK1 interaction efficiently suppresses the activity of AKT pathway and restricts tumor growth in vivo. Kristina Mäemets-Allas, Janeli Viil, and Viljar Jaks.</td>
</tr>
</tbody>
</table>
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Salvatore Lopez, Emiliano Coco, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L. Schwab, Diana P. English, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Corrado Terranova, Roberto Angioli, and Alessandro D. Santin

Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies
Silvia Calpe, Koen Wagner, Mohamed El Khattabi, Lucy Rutten, Cheryl Zimberlin, Edward Dolk, C. Theo Verrips, Jan Paul Medema, Hergen Spits, and Kausilia K. Krishnadath

Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer
Manuela Porru, Simona Artuso, Erica Salvati, Armandodoriano Bianco, Marco Franceschin, Maria Gazzia Diodoro, Daniela Passeri, Augusto Orlandi, Francesco Savorani, Maurizio D’Incalci, Annamaria Birocco, and Carlo Leonetti

Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors
Yonenee Seol, Hongliang Zhang, Keli Agama, Nicholas Lorence, Yves Pommier, and Keir C. Neuman

Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Yevgen Chornenkyy, Sameer Agnihotri, Man Yu, Pawel Buzzkowicz, Patricia Rakopoulos, Brian Golbourn, Livia Garzia, Robert Siddaway, Stephanie Leung, James T. Rutka, Michael D. Taylor, Peter B. Dirks, and Cynthia Hawkins

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Ravi K. Amaravadi, Russell J. Schiller, Lainie P. Martin, Myron Levin, Martin A. Graham, David E. Weng, and Alex A. Adjei

Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
Shanhu Hu, Yun Lu, Bernardo Orz, Cristina Godek, Lisa Maria Mustachio, Masanori Kawakami, David Sekula, Duane A. Compton, Sarah Freemantle, and Ethan Dmitrovsky

Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression
Zhiqun Shang, Yanjun Li, Minghao Zhang, Jing Tian, Ruifa Han, Chih-Rong Shyr, Edward Messing, Shuyuan Yeh, Yuanjie Niu, and Chawnshang Chang

Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5
Marianne Le Gall, Ronan Crépin, Madeline Neiveyans, Christian Auelra, Yongfeng Fan, Yu Zhou, James D. Marks, André Pélegrin, and Marie-Alix Poul

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody–Drug Conjugates
Rémy Gébleux, Sarah Wulhfard, Giulio Casì, and Dario Neri

Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity

HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells
Chien-Feng Li, Hsin-Hwa Tsai, Chiung-Yuan Ko, Yen-Chun Pan, Chia-Jui Yen, Hong-Yue Lai, Chiou-Hwa Yuh, Wan-Chen Wu, and Ju-Ming Wang
2634 Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Zhi Peng, Zhongwu Li, Jing Gao, Ming Lu, Jifang Gong, En-Tzu Tang, Kelly S. Oliner, Yong-Jiang Hei, Hui Zhou, and Lin Shen

2642 Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

2653 MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Jia-Quan Qu, Hong-Mei Yi, Xu Ye, Jin-Feng Zhu, Hong Yi, Li-Na Li, Tu Xiao, Li Yuan, Jiao-Yang Li, Yuan-Yuan Wang, Juan Feng, Qu-Yan He, Shan-Shan Lu, and Zhi-Qiang Xiao

MODELS AND TECHNOLOGIES

2665 A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion

ABOUT THE COVER
Early-stage cutaneous melanoma development is characterized by uncontrolled proliferation and invasion of melanoma cells from the epidermis into the dermis through the basement membrane. This process is modelled using a novel full-thickness human melanoma skin equivalent in which melanoma cells form nests at the epidermal/dermal junction, as seen in this image, the basement membrane component type IV collagen, before disrupting the basement membrane structure as they invade at later time points. For full details of this model and its use for the investigation of early melanoma invasion, see the article by Hill and colleagues on page 2665.